Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibodyKarin Staflin, Teemu T. JunttilaJCI InsightApril 8, 202010.1172/jci.insight.133757Cited by 97SaveCiteExport RISWatch citationsRelated PapersNo related papers foundPowered by citation graph analysis